TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06203678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: therapeutic tape application

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Cervical stretching and strengthening exercises home program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Cervical stretching and strengthening exercises home program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Cervical stretching and strengthening exercises home program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham taping
Description: patch tape application
Study: NCT05797350

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Drainage Device
Description: Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Drainage Device
Description: Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
Study: NCT05359627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
Study: NCT05042466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trauma
Description: 0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trauma
Description: 0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trauma
Description: 0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
Study: NCT05507164

Intervention type: DRUG
Group type: OTHER
Intervention: Temporomasseteric Nerve Block
Description: The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
Study: NCT06238700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pregnenolone
Description: Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills are identical-appearing capsules containing cellulose
Study: NCT05944393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Ultrasound-guided Erector Spine Plane block with 10 mL 0.5% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline 0.9% Injectable Solution
Description: Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
Study: NCT06570135

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detecting Brain Activity with Functional Near Infrared Spectroscopy
Description: Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detecting Brain Activity with Functional Near Infrared Spectroscopy
Description: Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.
Study: NCT04357093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape seed extract mouthwash
Description: Mouthwash 15% grape seed extract

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride mouthwash
Description: Sodium fluoride mouthwash
Study: NCT06223139

Intervention type: DIAGNOSTIC_TEST
Intervention: Handgrip strength
Description: Handgrip strength will be measured by 3 efforts.
Study: NCT04580888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early transthoracic echocardiography
Description: In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
Study: NCT06113614

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
Study: NCT04580888

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standards of care
Description: In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
Study: NCT06590454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrvinium
Description: Pyrvinium (2 mg/kg) per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14 days
Study: NCT06015191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Cardiac Rehabilitation
Description: Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
Study: NCT06397534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online.
Study: NCT06667167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Carboplatin
Description: Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
Study: NCT06611371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT GBS-06
Description: Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT GBS-06
Description: Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT GBS-06
Description: Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT06673069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION269
Description: Administered as intrathecal (IT) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION269
Description: Administered as intrathecal (IT) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION269
Description: Administered as intrathecal (IT) injection.
Study: NCT06113614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
Study: NCT04437537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable 3D electrospun synthetic matrix
Description: All participants in this study will receive PHOENIX Wound Matrix® in addition to the SOC treatment for their chronic DFU.
Study: NCT05039203

Intervention type: DEVICE
Intervention: Indwelling urinary catheter
Description: Removal of indwelling urinary catheter
Study: NCT06678880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase Advanced Intervention (PAI)
Description: Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase Delay Intervention (PDI)
Description: Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.
Study: NCT06138184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticoagulation Educational Materials
Description: This includes new web-based patient educational materials that have been developed prior to the start of the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Standard of Care
Description: This will be the current practice for patient education
Study: NCT06624228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Study participants will receive bimekizumab at pre-specified time points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Study participants will receive risankizumab at pre-specified time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo at pre-specified time points.
Study: NCT06113614

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Simulation of photobiomodulation
Description: The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
Study: NCT05049733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 1mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 1mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 1mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 1mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 2mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 2mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 2mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 2mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 4mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 4mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 4mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 4mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo CBD
Description: Participants will ingest soft gel tablets containing placebo for CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo CBD
Description: Participants will ingest soft gel tablets containing placebo for CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo CBD
Description: Participants will ingest soft gel tablets containing placebo for CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CBD
Description: Participants will ingest soft gel tablets containing placebo for CBD
Study: NCT05611125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Integrated Primary Care (TIPC)
Description: The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
Study: NCT06624228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study participants will receive placebo at pre-specified time points.
Study: NCT05378659

Intervention type: BEHAVIORAL
Intervention: Montreal Cognitive Assessment
Description: Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place

Intervention type: BEHAVIORAL
Intervention: Montreal Cognitive Assessment
Description: Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place

Intervention type: BEHAVIORAL
Intervention: Stroop Test
Description: Evaluates Processing Speed and Executive Control
Study: NCT06435793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEP measurement - Surface EMG - IOPI
Description: Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument.
Study: NCT05376423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBI-833/OBI-821
Description: OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
Study: NCT05701345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMNIFIT DTx-MDD
Description: This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.
Study: NCT06525454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized coaching messages for blood glucose and emotions
Description: For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.
Study: NCT04615988

Intervention type: OTHER
Intervention: blood draw and questionnaire completion
Description: questionaires provided to subjects during visits while on study and baseline one tube of blood drawn